OraLiva, Inc. is preparing to launch its first noninvasive, AI-powered oral cancer test following recent NIH funding support. The test combines microfluidics, cytology, and advanced image analysis to detect mild-to-severe dysplasia earlier and more accurately than visual exams alone.
The platform is also being developed into a cartridge-based, point-of-care device that can be used directly in dental and ENT offices, with an FDA submission planned in the coming years